The upcoming report from Frontdoor (FTDR) is expected to reveal quarterly earnings of $1.44 per share, indicating an increase of 13.4% compared to the year-ago period. Analysts forecast revenues of $602.1 million, representing an increase of 11.1% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earnings disclosure, it i ...

Wall Street analysts expect Ralph Lauren (RL) to post quarterly earnings of $3.45 per share in its upcoming report, which indicates a year-over-year increase of 27.8%. Revenues are expected to be $1.65 billion, up 8.8% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone an upward revision of 1.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a ...

Core Viewpoint - Analysts expect Gilead Sciences (GILD) to report quarterly earnings of $1.95 per share, reflecting a year-over-year decline of 3%, with revenues projected at $6.95 billion, down 0.1% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 1.1% higher in the last 30 days, indicating a collective reevaluation by analysts [1][2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [2]. Revenue Projections - Analysts project 'Revenues- Royalty contract and other revenues' to reach $38.09 million, indicating a decline of 7.1% year-over-year [3]. - The average prediction for 'Total product sales- Total' is $6.91 billion, showing no change from the prior year [4]. Product Sales Estimates - 'Product Sales- Oncology- Cell Therapy- Tecartus- Total' is estimated at $92.76 million, reflecting a decrease of 13.3% from the previous year [4]. - 'Product Sales- Veklury- Total' is expected to be $211.34 million, down 1.2% year-over-year, while 'Product Sales- HIV- Odefsey- U.S.' is projected at $215.50 million, down 7.5% [5]. - 'Product Sales- Other- Other- U.S.' is anticipated to be $54.28 million, indicating a significant decline of 44.6% [5]. - 'Product Sales- HIV- Descovy- U.S.' is expected to reach $509.35 million, reflecting a growth of 17.4% year-over-year [6]. - 'Product Sales- Oncology- Trodelvy- U.S.' is projected at $224.58 million, showing a slight increase of 0.3% [6]. - 'Product Sales- Oncology- Cell Therapy- Tecartus- U.S.' is estimated at $49.56 million, down 21.3% year-over-year [7]. - 'Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S.' is expected to be $225.96 million, down 15.4% [7]. - 'Product Sales- HIV- Genvoya- U.S.' is projected at $333.57 million, reflecting a decline of 10.3% [8]. - 'Product Sales- Veklury- U.S.' is expected to reach $69.13 million, down 9% year-over-year [8]. Market Performance - Gilead shares have increased by 1.3% over the past month, compared to a 0.6% increase in the Zacks S&P 500 composite [8].

Core Insights - Corpay (CPAY) is expected to report quarterly earnings of $5.13 per share, reflecting a year-over-year increase of 12.8% [1] - Anticipated revenues for the quarter are projected to be $1.1 billion, which represents a 12.7% increase compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised 1.2% higher over the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3] Revenue Forecasts - Analysts predict 'Revenues- Corporate Payments' will reach $385.68 million, a year-over-year increase of 33.7% [5] - 'Revenues- Vehicle Payments' are expected to be $525.69 million, showing a 3% increase year-over-year [5] - 'Revenues- Lodging Payments' are forecasted at $122.91 million, indicating a slight increase of 0.4% from the previous year [5] - 'Revenues- Other Payments' are estimated to be $61.97 million, reflecting a 13.5% increase from the prior year [6] Transaction and Operating Income Estimates - 'Spend volume - Corporate Payments' is projected to reach 54.03 million, up from 42.88 million in the same quarter last year [7] - 'Operating income- Corporate Payments' is expected to be $144.83 million, compared to $120.56 million in the previous year [9] - 'Operating income- Vehicle Payments' is forecasted at $259.50 million, up from $242.03 million year-over-year [9] - 'Operating income- Lodging' is estimated to be $55.18 million, slightly down from $56.39 million in the same quarter last year [10] Market Performance - Corpay shares have decreased by 6.7% in the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite [10]

The upcoming report from Realty Income Corp. (O) is expected to reveal quarterly earnings of $1.06 per share, indicating no change from the year-ago quarter. Analysts forecast revenues of $1.4 billion, representing an increase of 4.2% year over year.The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's ...

In its upcoming report, Iron Mountain (IRM) is predicted by Wall Street analysts to post quarterly earnings of $1.19 per share, reflecting an increase of 183.3% compared to the same period last year. Revenues are forecasted to be $1.68 billion, representing a year-over-year increase of 9.3%.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ov ...

Genius Sports Limited (GENI) shares ended the last trading session 10.6% higher at $11.25. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.7% gain over the past four weeks.Genius Sports is benefiting from its expanding partnership, innovative product launches like BetVision and SAOT, and its integration of GeniusIQ technology across sports ecosystems.This company is expected to post quarterly earnings of $0.00 pe ...

Core Viewpoint - Analysts project that Masco (MAS) will report quarterly earnings of $1.08 per share, reflecting a 10% decline year over year, with revenues expected to reach $2 billion, down 4.1% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 3.4% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Key Metrics - Analysts estimate 'Net Sales- Plumbing Products' to be $1.26 billion, representing a 0.5% increase year over year [5]. - The consensus for 'Net Sales- Decorative Architectural Products' is $744.34 million, indicating an 11.2% decline year over year [5]. - Expected 'Operating profit, as adjusted- Plumbing Products' is projected at $225.09 million, down from $249.00 million in the same quarter last year [6]. - Analysts forecast 'Operating profit, as adjusted- Decorative Architectural Products' at $145.41 million, compared to $174.00 million in the previous year [6]. - The projected 'Operating profit, as reported- Decorative Architectural Products' is $140.29 million, down from $174.00 million year over year [7]. - 'Operating profit, as reported- Plumbing Products' is expected to be $223.34 million, compared to $247.00 million in the same quarter last year [7]. Stock Performance - Over the past month, Masco shares have returned -0.7%, while the Zacks S&P 500 composite has changed by +3.4% [7]. - Masco holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [7].

Shares of Omnicom (OMC) have gained 3.7% over the past four weeks to close the last trading session at $74.63, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.56 indicates a potential upside of 25.4%.The mean estimate comprises nine short-term price targets with a standard deviation of $13.43. While the lowest estimate of $78.00 indicates a 4.5% increase from the current pri ...

Core Viewpoint - Analysts forecast Kinross Gold (KGC) will report quarterly earnings of $0.32 per share, reflecting a year-over-year increase of 128.6% and revenues of $1.35 billion, a 10.3% increase compared to the previous year [1]. Group 1: Earnings Estimates - The consensus EPS estimate has been revised 3.2% lower over the last 30 days, indicating a reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3]. Group 2: Key Metrics - The average realized gold price per ounce is estimated to reach $2885.45, up from $2342.00 in the same quarter last year [5]. - The production cost of sales per equivalent ounce sold is estimated at $1199, compared to $1029 in the previous year [5]. - The attributable all-in sustaining cost per equivalent ounce sold is projected at $1.57 billion, an increase from $1.39 billion year-over-year [6]. Group 3: Market Performance - Kinross Gold shares have returned +8.2% over the past month, outperforming the Zacks S&P 500 composite's +4.9% change [6]. - With a Zacks Rank 1 (Strong Buy), KGC is expected to outperform the overall market in the near future [6].